Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835806 | 0.87 | FYN (0.47) | FYNDYRK1AEGLN2 | |
| SCHEMBL834234 | 0.85 | FYN (0.67) | FYN | |
| SCHEMBL835970 | 0.82 | FYN (0.48) | FYNEGLN2FGFR1FGFR3 | |
| SCHEMBL836268 | 0.81 | FYN (0.45) | FYNFGFR1FGFR3 | |
| SCHEMBL835641 | 0.80 | FYN (0.49) | FYNDYRK1AEGLN2FGFR1FGFR3 | |
| SCHEMBL836996 | 0.79 | FYN (0.58) | FYNFGFR1FGFR3 | |
| SCHEMBL836699 | 0.78 | FYN (0.53) | FYNDYRK1AFGFR1FGFR3 | |
| SCHEMBL836186 | 0.76 | FGFR1 (0.65) | FYNFGFR1FGFR3 | |
| SCHEMBL835647 | 0.76 | FYN (0.52) | FYNFGFR1FGFR3 | |
| SCHEMBL834854 | 0.75 | FYN (0.45) | FYNFGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | claimed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | claimed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | claimed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | claimed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | claimed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | FYN 971/4885JAK2 285/4885JAK1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.